Avoid flooded roads, but follow these tips to navigate them safely if you have no other option
uae3 hours ago
Merck & Co. said on Friday that its experimental Covid-19 pill reduced hospitalisations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the US and around the world to authorise its use.
If cleared, Merck’s drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic. All Covid-19 therapies now authorised in the US require an IV or injection.
Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of Covid-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill.
The study tracked 775 adults with mild-to-moderate Covid-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease.
Among patients taking molnupiravir, 7.3 per cent were either hospitalized or died at the end of 30 days, compared with 14.1 per cent of those getting the dummy pill.
There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck. The results were released by the company and have not been peer reviewed. Merck said it plans to present them at a future medical meeting.
An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. Company executives said they are in discussions with the Food and Drug Administration and plan to submit the data for review in coming days.
“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr Dean Li, vice-president of Merck research. “When you see a 50 per cent reduction in hospitalisation or death, that’s a substantial clinical impact.”
Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.
Earlier study results showed the drug did not benefit patients who were already hospitalised with severe disease.
The US has approved one antiviral drug, remdesivir, specifically for Covid-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to given by IV or injection at hospitals or medical clinics, and supplies have been stretched by the latest surge of the delta variant.
Health experts, including the top US infectious disease expert Dr Anthony Fauci, have long called for a convenient pill that patients could take when Covid-19 symptoms first appear, much the way the decades-old flu medication Tamiflu helps fight influenza. Such medications are seen as key to controlling future waves of infection and reducing the impact of the pandemic.
Merck’s pill works by interfering with an enzyme the coronavirus uses to copy its genetic code and reproduce itself. It has shown similar activity against other viruses.
The US government has committed to purchase 1.7 million doses of the drug if it is authorised by the FDA. Merck has said it can produce 10 million doses by the end of the year and has contracts with governments worldwide. The company has not announced prices.
ALSO READ:
Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.
Merck had planned to enrol more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe and Africa. Executives estimated about 10 per cent of patients studied were from the US
Avoid flooded roads, but follow these tips to navigate them safely if you have no other option
uae3 hours ago
All relevant agencies are prepared to tackle the anticipated weather fluctuations by implementing proactive measures
uae3 hours ago
Concerned authorities in Dubai confirm their readiness to deal with the prevailing conditions
uae9 hours ago
Stoinis top-scored in Lucknow's modest chase of 145 against Mumbai as the home team achieved their target with four wickets and four balls to spare
cricket10 hours ago
According to the Met Department, inclement weather is expected to begin from the west by Wednesday night, extending over most areas of the country on Thursday
uae11 hours ago
The number of e& UAE subscribers reached 14.5 million in Q1 2024
telecom11 hours ago
National Emergency, Crisis and Disaster Management Authority confirmed its readiness to deal with inclement weather
uae12 hours ago
He will be among a 15-member squad headed to the United States and West Indies for the tournament starting June 1
cricket12 hours ago